179. Deputy Erin McGreehan asked the Minister for Health the way in which patient representatives, clinicians and advocacy groups will be involved in a review of the National Cancer Strategy 2017-2026; and if she will make a statement on the matter. [45983/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Erin McGreehan .
404 questions match, newest first.
180. Deputy Erin McGreehan asked the Minister for Health when the development of the new National Cancer Strategy will start; and if she will make a statement on the matter. [45984/26]
181. Deputy Erin McGreehan asked the Minister for Health the way in which patient representatives, clinicians and advocacy groups will be involved in the development of the next National Cancer Strategy; and if she will make a statement on the matter. [45985/26]
182. Deputy Erin McGreehan asked the Minister for Health the likelihood of the Tobacco Products Directive and Tobacco Advertising Directive files falling to the Irish Presidency to progress; and if she will make a statement on the matter. [45986/26]
183. Deputy Erin McGreehan asked the Minister for Health the progress made against each of the key performance indicators, as outlined on page 25 of the Framework for the Care and Support of Adolescents and Young Adults (AYA) with Cancer in Ireland 2021-2026; including what KPIs; and if she will make a statement on the matter. [45987/26]
1736. Deputy Erin McGreehan asked the Minister for Health the measures being considered at EU level, during Ireland’s Presidency, to ensure that SMEs and indigenous biotech companies involved in cell therapies, gene therapies and orphan drug development are not disproportionately impacted by increased regulatory obligations under the EU pharma package; and if she will make a statement on the matter. [42965/26]
2090. Deputy Erin McGreehan asked the Minister for Health if she is aware of the report 'Cancer Dashboard for Ireland' by the Swedish Institute for Health Economics; if she has reviewed the recommendations contained in it; and if she will give the report findings due consideration in the development of Ireland's next National Cancer Strategy. [42619/26]
2140. Deputy Erin McGreehan asked the Minister for Health for an update on allowing pharmacies to consult with patients and prescribe for the free contraception scheme; and if she will make a statement on the matter. [42934/26]
2141. Deputy Erin McGreehan asked the Minister for Health for a report on the delivery of the Endometriosis Action Plan; and if she will make a statement on the matter. [42935/26]
2145. Deputy Erin McGreehan asked the Minister for Health the number of faecal immunochemical testing tests conducted in each of the 25 sites currently utilising the service, broken down by CHO area and hospital group. [42962/26]
2146. Deputy Erin McGreehan asked the Minister for Health the specific positions Ireland will advocate during negotiations on the EU pharma package regarding incentives for the development and commercialisation of orphan medicines and advanced therapy medicinal products; and if she will make a statement on the matter. [42963/26]
2147. Deputy Erin McGreehan asked the Minister for Health the engagement her Department has had with Irish-based advanced therapy and rare disease stakeholders regarding the proposed changes to regulatory data protection and market exclusivity provisions under the EU pharma package; the concerns identified through this engagement; and if she will make a statement on the matter. [42964/26]
2148. Deputy Erin McGreehan asked the Minister for Health the role Ireland intends to play during its EU presidency in shaping the implementation of the Critical Medicines Act with regard to securing the supply chains for orphan medicines, advanced therapies and biologic medicines; and if she will make a statement on the matter. [42966/26]
2149. Deputy Erin McGreehan asked the Minister for Health the discussions taking place at EU level regarding the inclusion of advanced therapy medicinal products and orphan drugs within strategic stockpiling, procurement or supply resilience mechanisms under the Critical Medicines Act; and if she will make a statement on the matter. [42968/26]
2150. Deputy Erin McGreehan asked the Minister for Health the discussions taking place at EU level, in the context of the EU pharma package and Ireland’s forthcoming EU presidency, regarding greater cooperation between member states on access, pricing, reimbursement and procurement pathways for orphan medicines and advanced therapy medicinal products; and if she will make a statement on the matter. [42969/26]
1369. Deputy Erin McGreehan asked the Minister for Health to set out the full process and eligibility criteria for patients accessing the Northern Ireland Planned Healthcare Scheme; and to provide the number of applications, approvals, refusals and reimbursements issued under the scheme in each of the past three years, along with any planned changes or improvements. [39553/26]
1370. Deputy Erin McGreehan asked the Minister for Health to outline the process and administrative requirements for patients seeking treatment under the Cross Border Directive; and to provide the number of applications, approvals, refusals and reimbursements recorded under the scheme in each of the past three years, together with any planned changes or improvements. [39554/26]
1371. Deputy Erin McGreehan asked the Minister for Health to detail the process and eligibility criteria for patients accessing treatment through the National Treatment Purchase Scheme; and to provide the number of applications, approvals, refusals and reimbursements under the scheme in each of the past three years, as well as any planned changes or improvements. [39555/26]
1372. Deputy Erin McGreehan asked the Minister for Health to outline the full process and eligibility criteria for patients applying under the Treatment Abroad Scheme; and to provide the number of applications, approvals, refusals and reimbursements issued under the scheme in each of the past three years, together with any planned changes or improvements. [39556/26]
332. Deputy Erin McGreehan asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy. [38500/26]
306. Deputy Erin McGreehan asked the Minister for Health the expected completion date for the new hospice facility in Drogheda; whether an interim community palliative care model will be funded and operational in the Ardee-Drogheda-Dundalk corridor pending its opening; and if she will make a statement on the matter. [38307/26]
854. Deputy Erin McGreehan asked the Minister for Health if her Department plans to establish a rapid access pancreatic cancer diagnostic clinic to ensure assessment within two weeks of referral; and if she will make a statement on the matter. [31971/26]
855. Deputy Erin McGreehan asked the Minister for Health the steps being taken to reduce delays in diagnostic tests for suspected pancreatic cancer and to standardise pathways nationally; and if she will make a statement on the matter. [31972/26]
856. Deputy Erin McGreehan asked the Minister for Health if she will introduce a national awareness campaign on the early signs of pancreatic cancer; and if she will make a statement on the matter. [31973/26]
857. Deputy Erin McGreehan asked the Minister for Health for an update on the implementation of National Cancer Strategy commitments relating to rapid referral pathways for high mortality cancers such as pancreatic cancer; and if she will make a statement on the matter. [31974/26]